Pharma bosses face down investor angst on tariffs, HHS chaos
As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of US tariffs on their products.
As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of US tariffs on their products.
